Mass tort settlement payouts are calculated using a combination of factors that courts and settlement administrators have refined over decades of managing large-scale litigation. The core method involves determining the settlement fund’s total amount—negotiated between defendants and plaintiffs’ attorneys—then dividing it among eligible claimants based on injury severity, medical expenses, lost wages, and other damages specific to each case. In the Roundup (glyphosate) litigation, which produced a $10.9 billion settlement in 2021, claimants received payouts ranging from $5,000 to over $250,000 depending on whether they had non-Hodgkin’s lymphoma diagnoses and the quality of their medical documentation.
This allocation wasn’t arbitrary; it followed a detailed claims matrix that assigned point values to different injury levels and then distributed funds pro rata based on those points. The calculation process begins long before individual claimants see a check. Defense attorneys and plaintiffs’ counsel negotiate a total settlement figure, but they do not typically decide individual payouts at the negotiation table. Instead, they establish the framework—the claims evaluation criteria, the injury classifications, and the distribution methodology—and then hire a claims administrator to implement it fairly and uniformly across thousands or tens of thousands of claimants.
Table of Contents
- What Is a Claims Matrix and How Does It Determine Individual Payouts?
- How Are Funds Distributed When There’s Not Enough Money for Everyone?
- What Role Do Medical Records and Documentation Play in Valuation?
- How Do Defendants and Plaintiffs’ Attorneys Estimate the Total Settlement Fund?
- What Happens to Claims That Don’t Meet the Injury Criteria or Medical Standards?
- How Do Claims Administrators Handle Secondary Injuries or Complicating Medical Conditions?
- What Happens After the Settlement Fund Is Exhausted?
What Is a Claims Matrix and How Does It Determine Individual Payouts?
A claims matrix is a standardized payment schedule that assigns specific monetary values to different injury categories and severity levels. The matrix works by scoring each claim based on medical evidence, diagnosis confirmation, symptom severity, and documented damages. For example, in the Zantac (ranitidine) stomach cancer settlements that began resolving in 2024, claimants with confirmed gastric cancer and treatment records received significantly higher base valuations than those with pre-cancerous changes or borderline diagnoses. The matrix might assign a base value of $50,000 to Tier 1 (confirmed malignant cancer diagnosis with medical treatment), then adjust downward or upward based on factors like whether the person had prior medical conditions, whether they received chemotherapy, or how much time passed before diagnosis.
The matrix provides predictability but also creates real disparities in outcomes. Two claimants with the same diagnosis can receive different payments if one has more complete medical documentation than the other. A person who saw a specialist and received multiple diagnostic confirmations might be classified as Tier 2, while someone who received a diagnosis from a primary care physician without imaging studies might fall into Tier 3, even if their underlying condition is identical. Claims administrators have relatively little discretion to override the matrix; their role is to verify that the medical documentation supports the tier assignment, then apply the formula mechanically.
How Are Funds Distributed When There’s Not Enough Money for Everyone?
One of the most challenging aspects of settlement administration is the pro rata shortfall—the situation where the total settlement fund cannot pay every claim at its full matrix value. This happens frequently. When claims are submitted, administrators calculate the total liability across all approved claims. If approved claims total $12 billion but the settlement fund is only $10 billion, every claimant receives a pro rata reduction, typically 83 cents on the dollar. The pro rata calculation is deceptively simple in concept but brutal in execution. Every approved claim, regardless of injury severity, receives the same percentage reduction. A claimant whose matrix value was $200,000 receives $166,000.
A claimant whose matrix value was $10,000 receives $8,300. Courts have consistently upheld pro rata distribution as the fairest method when funds are insufficient, because any alternative—prioritizing certain claims over others—would favor some claimants and disadvantage others arbitrarily. However, claimants often feel cheated by this outcome, particularly if they have severe injuries and discover their payout is significantly less than anticipated. The risk of pro rata shortfalls creates an incentive for claimants to submit claims early. Many settlements establish a filing deadline—often 12 to 24 months after the settlement is approved—and claims submitted before the deadline share the pool equally. Claims submitted after the deadline may be paid from remaining funds at reduced rates or rejected entirely. This mechanism encourages participation but also creates rushed submissions with incomplete documentation, which can lead to lower tier assignments and further payment reductions.
What Role Do Medical Records and Documentation Play in Valuation?
Medical records are the foundation of nearly every payout calculation. Claims administrators hire medical professionals—physicians or nurses—to review submitted documentation and assign injury classifications. The standard is not what a claimant believes they are owed, but what the medical records objectively demonstrate. A claimant might have suffered serious symptoms, but if those symptoms were never documented in medical records, the claim will be valued based on whatever was recorded. This creates a significant advantage for claimants who sought medical care throughout the relevant exposure period and who have organized, complete records. In the talc litigation (johnson & Johnson settlements totaling $8.9 billion from 2022 onward), claimants with pathology reports confirming ovarian cancer, surgical records, and oncology treatment histories received the highest valuations.
Claimants without pathology confirmation—for instance, those diagnosed clinically based on symptoms and imaging alone—often fell into lower tiers and received smaller payouts. A claimant with identical symptoms but no biopsy confirmation might receive 30-50% less than someone with identical symptoms and a confirmed tissue diagnosis. The evidentiary standard is particularly strict for diseases with long latency periods, such as mesothelioma. A mesothelioma claimant must provide pathology confirmation (a tissue sample showing malignant mesothelioma), imaging studies (CT or MRI showing pleural thickening or asbestos-related changes), and medical records documenting the disease progression. Claimants who cannot produce pathology reports—perhaps because their diagnosis was made at an advanced stage when biopsy was not performed—often see their claims valued at 20-40% of what they would receive with full documentation. Courts have ruled that settlements are free to require rigorous proof, even if it disadvantages claimants with legitimate injuries but incomplete records.
How Do Defendants and Plaintiffs’ Attorneys Estimate the Total Settlement Fund?
The negotiation of a settlement’s total fund amount involves complex economic modeling. Plaintiffs’ attorneys estimate the number of potential claimants, their average injury severity based on prior litigation or epidemiological data, and typical jury awards in comparable cases. Defendants want to minimize their liability while ensuring the settlement is adequate—too small, and the settlement will be rejected by the court or claimants will opt out to pursue individual cases; too large, and shareholders or stakeholders will object. In some cases, the parties use epidemiological data from prior settlements to forecast claim rates and severity. The asbestos litigation, which has produced over $150 billion in settlements since the 1980s, established historical benchmarks that newer settlements reference.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
For example, if prior asbestos settlements saw 30,000 to 50,000 claims submitted in a five-year period, and average payouts were $90,000 per claim, new settlements are sized based on updated versions of those figures, adjusted for medical inflation and changing diagnostic practices. The total fund amount also reflects the strength of the underlying litigation. If plaintiffs’ attorneys believe they have strong evidence of causation and damages, they will demand a higher settlement. If defendants have strong defenses or questions about liability, they will offer less. A settlement in a pharmaceutical mass tort where the drug company admits no wrongdoing but agrees to settle for “business reasons” often results in lower total funds than a settlement following trial victories against the defendant. The Purdue Pharma opioid settlement reached $6 billion, but that figure was controversial and hotly negotiated precisely because parties disagreed on how many claimants would submit claims and what their injuries were worth.
What Happens to Claims That Don’t Meet the Injury Criteria or Medical Standards?
Not every claim submitted is approved. Administrators reject claims for insufficient documentation, lack of medical evidence, or failure to meet the injury criteria specified in the settlement agreement. The claims administrator must apply the settlement’s eligibility criteria consistently, and many claimants receive denial letters. A typical rejection reason is “no confirmed diagnosis.” A claimant submits medical records showing they reported symptoms to a physician, but the physician never ordered diagnostic testing or the results were inconclusive. Administrators can only classify and pay claims based on what the medical record shows, not on what a claimant believes their condition was.
Claimants have limited appeal rights; most settlements allow a single appeal or administrative review, but rarely more. Claimants who are denied can pursue their own lawsuits, but that option is expensive and uncertain. Another common rejection reason is missing documentation entirely. Some claimants have no medical records from the relevant exposure period or have records from many years after exposure ended that cannot establish when the condition originated. The settlement agreement typically requires claimants to prove that their injury was plausibly caused by the defendant’s product, and absence of contemporaneous medical evidence makes that difficult. Claimants sometimes submit employment records, witness statements, or other circumstantial evidence, but medical records remain the gold standard and their absence is nearly always fatal to a claim.
How Do Claims Administrators Handle Secondary Injuries or Complicating Medical Conditions?
Many claimants have pre-existing conditions or secondary injuries that complicate their claims. A claimant with mesothelioma who also has lung cancer, heart disease, or diabetes will likely have that complexity reflected in their medical records and the administrator’s valuation. Some settlements include specific adjustments for comorbidities—conditions that coexist with the primary injury.
In the talc litigation, claimants with ovarian cancer and concurrent hypertension, diabetes, or obesity sometimes received slight valuation adjustments because those conditions affected treatment decisions or outcomes. However, settlements typically do not offer significant upward adjustments for comorbidities; instead, the medical record review documents these conditions to ensure the primary injury classification is accurate. A claimant’s secondary conditions generally do not increase their payout unless the settlement agreement specifically provides for such adjustments, which is rare.
What Happens After the Settlement Fund Is Exhausted?
Once all approved claims are paid and the settlement fund is depleted, claims administration ends. Any claimants who missed the filing deadline or who were not eligible under the settlement agreement have no further recourse through the settlement. They can pursue individual lawsuits against the defendant, but most do not, because litigation is expensive and the defendant has already achieved global peace through the settlement agreement.
Some settlements establish a “claims-made” process where claims must be filed within a specific window—often 12 to 24 months—and any claims filed after that date receive lower priority or reduced payments from remaining funds. After the settlement fund is exhausted, no more payments are made. In the asbestos litigation, some historical settlements ran out of money within 10-15 years of being established, and subsequent claimants had to pursue individual claims or seek compensation from bankruptcy trusts. The total amount of compensation available through all asbestos settlements and bankruptcy trusts now exceeds $150 billion, but individual claimants sometimes receive nothing if they missed filing deadlines or if all available funds were depleted.
- —
You Might Also Like
- Supreme Court ruling forces mistrial in major herbicide injury lawsuit settlement
- Purdue Pharma Faces Dissolution Following Five Billion Dollar Opioid Settlement Judgment
- Opioid Crisis Settlement Allocates Resources for Substance Abuse Treatment in Rural Kentucky